Janux Therapeutics (JANX) Total Current Liabilities: 2020-2025
Historic Total Current Liabilities for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $27.8 million.
- Janux Therapeutics' Total Current Liabilities rose 62.06% to $27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.8 million, marking a year-over-year increase of 62.06%. This contributed to the annual value of $17.5 million for FY2024, which is 33.96% up from last year.
- According to the latest figures from Q3 2025, Janux Therapeutics' Total Current Liabilities is $27.8 million, which was up 30.18% from $21.4 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Total Current Liabilities registered a high of $27.8 million during Q3 2025, and its lowest value of $9.2 million during Q2 2021.
- For the 3-year period, Janux Therapeutics' Total Current Liabilities averaged around $16.8 million, with its median value being $17.2 million (2024).
- In the last 5 years, Janux Therapeutics' Total Current Liabilities surged by 302.29% in 2021 and then tumbled by 35.52% in 2024.
- Janux Therapeutics' Total Current Liabilities (Quarterly) stood at $12.8 million in 2021, then grew by 28.99% to $16.5 million in 2022, then dropped by 21.05% to $13.0 million in 2023, then surged by 33.96% to $17.5 million in 2024, then surged by 62.06% to $27.8 million in 2025.
- Its Total Current Liabilities was $27.8 million in Q3 2025, compared to $21.4 million in Q2 2025 and $17.5 million in Q1 2025.